Evidence map›Paper›PMID 38543276›Full record

ArticlePharmaceutics2024

A New Algorithm Integrating Molecular Response, Toxicity, and Plasma Level Measures for Ponatinib Dose Choice in Patients Affected by Chronic Myeloid Leukemia.

Sara Galimberti, Elisabetta Abruzzese, Giacomo Luci, Claudia Baratè, Luigia Luciano, Alessandra Iurlo, Giovanni Caocci, Riccardo Morganti, Fabio Stefanelli, Antonello Di Paolo

Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06119269 (Ponatinib in cHronic myelOid LEukemia patieNts In Chronic phaSe), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06119269 recruitingnot on this map

Ponatinib in cHronic myelOid LEukemia patieNts In Chronic phaSe: the PHOENICS Protocol

TypeobservationalSponsorUniversity of PisaRan2023 to 2025Enrolled100ConditionsChronic Myeloid Leukemia, Chronic PhaseArmsTherapeutic drug monitoring, Molecular Response
3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Sara GalimbertiDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Elisabetta AbruzzeseHematology, Sant'Eugenio Hospital, Tor Vergata University, ASL Roma 2, 00133 Rome, Italy.ORCID 0000-0001-5228-6491
Giacomo LuciDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.
Claudia BaratèHematology Division, Pisa University Hospital, 56126 Pisa, Italy.ORCID 0000-0003-1006-2400
Luigia LucianoHematology, Federico II University, 80138 Naples, Italy.
Alessandra IurloHematology Division, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, 20122 Milan, Italy.ORCID 0000-0002-4401-0812
Giovanni CaocciHematology Unit, Businco Hospital, ARNAS Giuseppe Brotzu, 09121 Cagliari, Italy.ORCID 0000-0002-6585-5187
Riccardo MorgantiHematology Division, Pisa University Hospital, 56126 Pisa, Italy.ORCID 0000-0001-7783-0262
Fabio StefanelliForensic Toxicology, Pisa University Hospital, 56126 Pisa, Italy.ORCID 0000-0002-3211-6417
Antonello Di PaoloDepartment of Clinical and Experimental Medicine, University of Pisa, 56126 Pisa, Italy.ORCID 0000-0002-2661-6183
University of Pisa · ITASL Roma · ITAzienda Ospedaliera G. Brotzu · ITFederico II University Hospital · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ponatinib may be effective in chronic myeloid leukemia (CML) patients after failure of first/second line therapies. Although its efficacy for minimum plasma concentrations (C

Indexed as

chronic myeloid leukemiamolecular responseponatinibtherapeutic drug monitoringtoxicity

Identifiers

PMID38543276
PMCPMC10975223
OpenAlexW4392662341

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.